AGSW(600199)2023-04-27 16:00Financial Performance - The total operating revenue for Q1 2023 was RMB 432,469,904.21, an increase of 25.5% compared to RMB 344,642,502.13 in Q1 2022[24] - The total operating costs for Q1 2023 were RMB 474,441,914.80, up 29.3% from RMB 366,698,305.00 in Q1 2022[24] - The company reported a net loss attributable to shareholders of RMB -41,161,469.42 for Q1 2023, compared to a loss of RMB -12,545,004.17 in Q1 2022[26] - The basic and diluted earnings per share for Q1 2023 were both RMB -0.0626, compared to RMB -0.0191 in Q1 2022[26] - The company reported a total comprehensive loss of RMB -40,471,051.98 for Q1 2023, compared to a loss of RMB -12,239,161.55 in Q1 2022[26] - The company’s total liabilities and equity structure indicates a need for strategic adjustments to improve financial stability[33] Cash Flow - The net cash inflow from operating activities was RMB 490,852,262.38, compared to RMB 343,985,313.90 in the same period last year, reflecting a significant increase[11] - The net cash flow from operating activities was -¥1,343,025.35, showing a significant decline[52] - The company’s cash and cash equivalents decreased by ¥31,930,880.34, reflecting a challenging cash flow situation[35] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,415,988,659.80, an increase of 0.63% compared to the previous year[33] - The total liabilities amounted to ¥901,763,778.97, up from ¥839,745,142.92[60] - Equity attributable to shareholders decreased by 1.62% to ¥2,503,806,638.96 from ¥2,545,029,038.17[33] - The total equity attributable to shareholders was ¥2,503,806,638.96, down from ¥2,545,029,038.17[60] Research and Development - The research and development expenses for Q1 2023 were RMB 2,327,116.58, a decrease of 70.3% from RMB 7,819,598.36 in Q1 2022[24] - Research and development expenses decreased by 70.24%, indicating a reduction in investment in this area[35] Shareholder Information - The top shareholder, Anhui Jinzhongzi Group Co., Ltd., holds 27.1% of the shares, totaling 178,257,084 shares[18] Other Income and Expenses - The company received government subsidies amounting to RMB 1,588,672.74 during the reporting period[3] - The company reported a significant decrease in other income by 82.77%, attributed to a reduction in government subsidies compared to the previous year[35] - The company experienced a fair value loss of RMB -12,605.53 from investment income during the reporting period[24] Receivables - Accounts receivable increased by 32.82%, primarily due to increased credit sales to pharmaceutical customers[53] - Other receivables rose by 36.71%, mainly due to an increase in funds for the new product launch[53] Return on Assets - The weighted average return on net assets decreased by 1.17 percentage points to -1.63%[52]